Top

Published in:

Open Access 27-02-2023 | Rhabdomyosarcoma | ESPR

Imaging in rhabdomyosarcoma: a patient journey

Authors: Isabelle S. A. de Vries, Roelof van Ewijk, Laura M. E. Adriaansen, Anneloes E. Bohte, Arthur J. A. T. Braat, Raquel Dávila Fajardo, Laura S. Hiemcke-Jiwa, Marinka L. F. Hol, Simone A. J. ter Horst, Bart de Keizer, Rutger R. G. Knops, Michael T. Meister, Reineke A. Schoot, Ludi E. Smeele, Sheila Terwisscha van Scheltinga, Bas Vaarwerk, Johannes H. M. Merks, Rick R. van Rijn

Published in: Pediatric Radiology | Issue 4/2023

Abstract

Rhabdomyosarcoma, although rare, is the most frequent soft tissue sarcoma in children and adolescents. It can present as a mass at nearly any site in the body, with most common presentations in the head and neck, genitourinary tract and extremities. The optimal diagnostic approach and management of rhabdomyosarcoma require a multidisciplinary team with multimodal treatment, including chemotherapy and local therapy. Survival has improved over the last decades; however, further improvement in management is essential with current 5-year overall survival ranging from 35% to 100%, depending on disease and patient characteristics. In the full patient journey, from diagnosis, staging, management to follow-up after therapy, the paediatric radiologist and nuclear physician are essential members of the multidisciplinary team. Recently, guidelines of the European paediatric Soft tissue sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology (ESPR), in an ongoing collaboration with the International Soft-Tissue Sarcoma Database Consortium, provided guidance for high-quality imaging. In this educational paper, given as a lecture during the 2022 postgraduate ESPR course, the multi-disciplinary team of our national paediatric oncology centre presents the journey of two patients with rhabdomyosarcoma and discusses the impact on and considerations for the clinical (paediatric) radiologist and nuclear physician. The key learning points of the guidelines and their implementation in clinical practice are highlighted and up-to-date insights provided for all aspects from clinical suspicion of rhabdomyosarcoma and its differential diagnosis, to biopsy, staging, risk stratification, treatment response assessment and follow-up.

Available only for authorised users

Ferrari A, Brecht IB, Gatta G et al (2019) Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110:120–126. https://doi.org/10.1016/j.ejca.2018.12.031CrossRefPubMed

Wyatt KD, Birz S, Hawkins DS, Minard‐Colin V, Rodeberg DA, Sparber‐Sauer M, Bisogno G, Koscielniak E, De Salvo GL, Ebinger M, Merks JH (2022) Creating a data commons: the international soft tissue sarcoma consortium (INSTRuCT). Pediatr Blood Cancer 69(11):e29924. https://doi.org/10.1002/pbc.29924

Martin-Giacalone BA, Weinstein PA, Plon SE, Lupo PJ (2021) Pediatric rhabdomyosarcoma: epidemiology and genetic susceptibility. J Clin Med 10. https://doi.org/10.3390/jcm10092028

Meister MT, Koerkamp MJAG, Souza T de, et al (2022) Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. 1–23. https://doi.org/10.15252/emmm.202216001

Gripp KW (2005) Tumor predisposition in Costello syndrome. American Journal of Medical Genetics - Seminars in Medical Genetics 137 C:72–77. https://doi.org/10.1002/ajmg.c.30065

Li H, Sisoudiya SD, Martin-Giacalone BA et al (2021) Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the children’s oncology group. J Natl Cancer Inst 113:875–883. https://doi.org/10.1093/jnci/djaa204CrossRefPubMed

Kratz CP, Rapisuwon S, Reed H et al (2011) Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 157:83–89. https://doi.org/10.1002/ajmg.c.30300CrossRefPubMedCentral

Kratz CP, Freycon C, Maxwell KN et al (2021) Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: an International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol 7:1800–1805. https://doi.org/10.1001/jamaoncol.2021.4398CrossRefPubMed

Hartley AL, Birch JM, Marsden HB et al (1988) Neurofibromatosis in children with soft tissue sarcoma. Pediatr Hematol Oncol 5:7–16. https://doi.org/10.3109/08880018809031246CrossRefPubMed

10.

Shuman C, Beckwith BJ, Weksberg R (2000) Beckwith-Wiedemann Syndrome Synonym: Wiedemann-Beckwith Syndrome. [Updated 2016 Aug 11]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022

11.

Bisogno G, de Salvo GL, Bergeron C et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma ( RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. https://doi.org/10.1016/S1470-2045(19)30617-5CrossRefPubMed

12.

Bisogno G, Jenney M, Bergeron C et al (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19:1061–1071. https://doi.org/10.1016/S1470-2045(18)30337-1CrossRefPubMed

13.

Schoot RA, Chisholm JC, Casanova M et al (2022) Metastatic rhabdomyosarcoma: results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 study and pooled analysis with the concurrent BERNIE Study. J Clin Oncol. https://doi.org/10.1200/jco.21.02981CrossRefPubMedPubMedCentral

14.

Hibbitts E, Bradley JA, Rudzinski ER, et al (2019) Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors : a report from the Children ’ s Oncology Group. 6437–6448. https://doi.org/10.1002/cam4.2504

15.

Gallego S, Zanetti I, Orbach D et al (2018) Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer 124:3201–3209. https://doi.org/10.1002/cncr.31553CrossRefPubMed

16.

Bergeron C, Jenney M, de Corti F et al (2021) Embryonal rhabdomyosarcoma completely resected at diagnosis: the European paediatric Soft tissue sarcoma Study Group RMS2005 experience. Eur J Cancer 146:21–29. https://doi.org/10.1016/j.ejca.2020.12.025CrossRefPubMed

17.

van Ewijk R, Schoot RA, Sparber-Sauer M et al (2021) European guideline for imaging in paediatric and adolescent rhabdomyosarcoma — joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of. Pediatr Radiol 51:1940–1951. https://doi.org/10.1007/s00247-021-05081-0CrossRefPubMedPubMedCentral

18.

Hawkins DS. Bisogno G, Koscielniak E (2023) Introducing INSTRuCT: An international effort to promote cooperation and data sharing. Pediatr Blood Cancer 7(3):e28701

19.

Hawkins DS, Bisogno G, Koscielniak E (2020) Introducing INSTRuCT: an international effort to promote cooperation and data sharing. Pediatr Blood Cancer 1–2. https://doi.org/10.1002/pbc.28701

20.

Jacobson JA, Middleton WD, Allison SJ et al (2022) Ultrasonography of superficial soft-tissue masses: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 304:18–30. https://doi.org/10.1148/radiol.211101CrossRefPubMed

21.

Humphries PD, Sebire NJ, Siegel MJ, Olsen ØE (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245:848–854. https://doi.org/10.1148/radiol.2452061535CrossRefPubMed

22.

Fliedner FP, Engel TB, El-Ali HH et al (2020) Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response. BMC Cancer 20:1–9. https://doi.org/10.1186/s12885-020-6617-xCrossRef

23.

Clemente EJI, Navallas M, de la Torre IBM et al (2020) Mri of rhabdomyosarcoma and other soft-tissue sarcomas in children. Radiographics 40:791–814. https://doi.org/10.1148/rg.2020190119CrossRef

24.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026CrossRefPubMed

25.

Schoot RA, McHugh K, van Rijn RR et al (2013) Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology 269:870–878. https://doi.org/10.1148/radiol.13122607CrossRefPubMed

26.

Oliveira MP, de Lima PM, A, da Silva HJ, de Mello RJV, (2014) Neoplasm seeding in biopsy tract of the musculoskeletal system. A systematic review Acta Ortop Bras 22:106–110CrossRefPubMed

27.

Rogers T, Craigie R, Dall’igna P, Minard-colin V (2018) Surgery Guidelines Rhabdomyosarcoma European Paediatric Soft Tissue Sarcoma Study Group. European Pediatric Soft Tissue Sarcoma Study Group 1–18

28.

Rogers TN, Seitz G, Fuchs J et al (2021) Surgical management of paratesticular rhabdomyosarcoma: a consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 68:1–10. https://doi.org/10.1002/pbc.28938CrossRef

29.

World Health Organization (WHO) (2020) WHO classification of tumours: soft tissue and bone tumours , 4th ed. Lyon, France

30.

Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 59:5–10. https://doi.org/10.1002/pbc.24118CrossRefPubMedPubMedCentral

31.

Ognjanovic S, Linabery A, Charbonneau G, Ross J (2009) Trends in childhood RMS incidence and survival in the US. Cancer 115:4218–4226. https://doi.org/10.1002/cncr.24465.TrendsCrossRefPubMed

32.

Rudzinski ER, Kelsey A, Vokuhl C et al (2021) Pathology of childhood rhabdomyosarcoma: a consensus opinion document from the Children’s Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 68:1–10. https://doi.org/10.1002/pbc.28798CrossRef

33.

Missiaglia E, Williamson D, Chisholm J et al (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30:1670–1677. https://doi.org/10.1200/JCO.2011.38.5591CrossRefPubMed

34.

Williamson D, Missiaglia E, de Reyniès A et al (2010) Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28:2151–2158. https://doi.org/10.1200/JCO.2009.26.3814CrossRefPubMed

35.

Haduong JH, Heske CM, Allen‐Rhoades W, Xue W, Teot LA, Rodeberg DA, Donaldson SS, Weiss A, Hawkins DS, Venkatramani R (2022) An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer 69(4):e29511. https://doi.org/10.1002/pbc.29511

36.

Maurer HM, Crist W, Lawrence W et al (1988) The intergroup rhabdomyosarcoma study-I. A final report Cancer 61:209–220. https://doi.org/10.1002/1097-0142(19880115)61:2%3c209::AID-CNCR2820610202%3e3.0.CO;2-LCrossRefPubMed

37.

Beverly Raney R, Maurer HM, Anderson JR et al (2001) The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5:9–15. https://doi.org/10.1080/13577140120048890CrossRef

38.

Oberlin O, Rey A, Lyden E et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European Cooperative Groups. J Clin Oncol 26:2384–2389. https://doi.org/10.1200/JCO.2007.14.7207CrossRefPubMedPubMedCentral

39.

Terwisscha van Scheltinga CEJ, Wijnen MHWA, Martelli H et al (2022) In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities: analysis of the EpSSG RMS 2005 study. Eur J Surg Oncol 48:1536–1542. https://doi.org/10.1016/j.ejso.2022.03.001CrossRefPubMed

40.

Morris CD, Tunn PU, Rodeberg DA, et al (2020) Surgical management of extremity rhabdomyosarcoma: a consensus opinion from the Children’s Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 1–8. https://doi.org/10.1002/pbc.28608

41.

Li WJ, Chu ZG, Zhang Y et al (2019) Effect of slab thickness on the detection of pulmonary nodules by use of CT maximum and minimum intensity projection. Am J Roentgenol 213:562–567. https://doi.org/10.2214/AJR.19.21325CrossRef

42.

Samim A, Littooij AS, van den Heuvel-Eibrink MM et al (2017) Frequency and characteristics of pulmonary nodules in children at computed tomography. Pediatr Radiol 47:1751–1758. https://doi.org/10.1007/s00247-017-3946-2CrossRefPubMedPubMedCentral

43.

Vaarwerk B, Bisogno G, McHugh K et al (2019) Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma: are they clinically significant? A report from the European Paediatric Soft Tissue Sarcoma Study Group. J Clin Oncol 37:723–730. https://doi.org/10.1200/JCO.18.01535

44.

Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354. https://doi.org/10.1007/s00259-014-2961-xCrossRefPubMed

45.

Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 37:181–200. https://doi.org/10.1007/s00259-009-1297-4CrossRefPubMed

46.

Vali R, Alessio A, Balza R et al (2021) SNMMI procedure standard/EANM practice guideline on pediatric 18F-FDG PET/CT for oncology 1.0. J Nucl Med 62:99–110. https://doi.org/10.2967/jnumed.120.254110CrossRefPubMedPubMedCentral

47.

Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257–1260. https://doi.org/10.1080/10428190903040048CrossRefPubMed

48.

Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058. https://doi.org/10.1200/JCO.2013.53.5229CrossRefPubMedPubMedCentral

49.

Ferrari A, Trama A, de Paoli A et al (2017) Access to clinical trials for adolescents with soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatr Blood Cancer 64:1–6. https://doi.org/10.1002/pbc.26348CrossRef

50.

Chisholm JC, Merks JHM, Casanova M et al (2017) Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer 83:177–184. https://doi.org/10.1016/j.ejca.2017.06.015CrossRefPubMed

51.

Arndt CAS, Bisogno G, Koscielniak E (2018) Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev 68:94–101. https://doi.org/10.1016/j.ctrv.2018.06.013CrossRefPubMed

52.

Rhee DS, Rodeberg DA, Baertschiger RM et al (2020) Update on pediatric rhabdomyosarcoma: a report from the APSA Cancer Committee. J Pediatr Surg 55:1987–1995CrossRefPubMed

53.

Casey DL, Mandeville H, Bradley JA et al (2022) Local control of parameningeal rhabdomyosarcoma: an expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatr Blood Cancer 69:1–10. https://doi.org/10.1002/pbc.29751CrossRef

54.

Ferrari A, Bergamaschi L, Chiaravalli S, et al (2022) Metastatic rhabdomyosarcoma: evidence of the impact of radiotherapy on survival. A retrospective single‐center experience. Pediatr Blood Cancer 1–8. https://doi.org/10.1002/pbc.29853

55.

Palmer JD, Tsang DS, Tinkle CL, et al (2021) Late effects of radiation therapy in pediatric patients and survivorship. Pediatr Blood Cancer 68. https://doi.org/10.1002/pbc.28349

56.

Buwalda J, Schouwenburg PF, Blank LECM et al (2003) A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur J Cancer 39:1594–1602. https://doi.org/10.1016/S0959-8049(03)00363-0CrossRefPubMed

57.

Schoot RA, Slater O, Ronckers CM et al (2015) Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Eur J Cancer 51:1424–1434. https://doi.org/10.1016/j.ejca.2015.02.010CrossRefPubMed

58.

Schoot RA, Saeed P, Freling NJ, et al (2016) Local resection and brachytherapy for primary orbital rhabdomyosarcoma: outcome and failure pattern analysis. In: Ophthalmic Plastic and Reconstructive Surgery. Lippincott Williams and Wilkins, pp 354–360

59.

Blank LECM, Koedooder K, Pieters BR et al (2009) The AMORE protocol for advanced-stage and recurrent nonorbital rhabdomyosarcoma in the head-and-neck region of children: a radiation oncology view. Int J Radiat Oncol Biol Phys 74:1555–1562. https://doi.org/10.1016/j.ijrobp.2008.10.029CrossRefPubMed

60.

Vaarwerk B, Hol MLF, Schoot RA et al (2019) AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma. Radiother Oncol 131:21–26. https://doi.org/10.1016/j.radonc.2018.10.036CrossRefPubMed

61.

Chargari C, Haie-Meder C, Guérin F et al (2017) Brachytherapy combined with surgery for conservative treatment of children with bladder neck and/or prostate rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 98:352–359. https://doi.org/10.1016/j.ijrobp.2017.02.026CrossRefPubMed

62.

Lautz TB, Martelli H, Fuchs J et al (2020) Local treatment of rhabdomyosarcoma of the female genital tract: expert consensus from the Children’s Oncology Group, the European Soft-Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.28601CrossRefPubMedPubMedCentral

63.

Defachelles AS, Bogart E, Casanova M et al (2021) Randomized phase II trial of vincristine-irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: a European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer. J Clin Oncol 39:2979–2990. https://doi.org/10.1200/JCO.21.00124CrossRefPubMed

64.

van Ewijk R, Vaarwerk B, Breunis WB et al (2021) The value of early tumor size response to chemotherapy in pediatric rhabdomyosarcoma. Cancers (Basel) 13:1–15. https://doi.org/10.3390/cancers13030510CrossRef

65.

Dantonello TM, Stark M, Timmermann B et al (2015) Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma. Pediatr Blood Cancer 62:16–23. https://doi.org/10.1002/pbc.25207CrossRefPubMed

66.

Ferrari A, Miceli R, Meazza C et al (2010) Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 28:1322–1328. https://doi.org/10.1200/JCO.2009.25.0803CrossRefPubMed

67.

Oberlin O, Rey A, Sanchez De Toledo J et al (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr. J Clin Oncol 30:2457–2465. https://doi.org/10.1200/JCO.2011.40.3287CrossRefPubMed

68.

Chisholm JC, Marandet J, Rey A et al (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29:1319–1325. https://doi.org/10.1200/JCO.2010.32.1984CrossRefPubMed

69.

McHugh K, Roebuck DJ (2014) Review: Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. Pediatr Blood Cancer 61:3–6. https://doi.org/10.1002/pbcCrossRefPubMed

70.

Holme BM, Løberg M et al (2019) Revisiting surveillance schemes for cancer survivors. Ann Oncol 30:881–883. https://doi.org/10.1093/annonc/mdz107CrossRefPubMed

71.

Shah M, Denlinger CS (2015) Optimal post-treatment surveillance in cancer survivors: is more really better? Oncology (Williston Park) 230–240

72.

Jeffery G, Hickey B, Hider P (2002) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd002200CrossRefPubMed

73.

Wille-Jørgensen P, Syk I, Smedh K et al (2018) Effect of more vs less frequent follow-up testing on overall and colorectal cancer–specific mortality in patients with stage II or III colorectal cancer the COLOFOL randomized clinical trial. JAMA - Journal of the American Medical Association 319:2095–2103. https://doi.org/10.1001/jama.2018.5623CrossRefPubMed

74.

Portman D (2018) Scanxiety. Fam Syst. Health 36:415

75.

Bui KT, Liang R, Kiely BE, et al (2021) Scanxiety: a scoping review about scan-associated anxiety. BMJ Open 11. https://doi.org/10.1136/bmjopen-2020-043215

76.

Vaarwerk B, Mallebranche C, Affinita MC et al (2020) Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. Cancer 126:823–831. https://doi.org/10.1002/cncr.32603CrossRefPubMed

77.

Mindrup R (2022) Imprint of “Scanxiety.” AMA J Ethics 11:685–693

78.

Fetzko S, Fonseca A, Frances Wedekind M, Gupta AA, Setty BA, Schraw J, Lupo PJ, Guillerman RP, Butala AA, Russell H, Nicholls L, Walterhouse D, Hawkins DS, Okcu MF (2022) Is detection of relapse by surveillance imaging associated with longer survival in patients with rhabdomyosarcoma? Pediatr. Hematol Oncol J 44(6):305–312. https://doi.org/10.1097/MPH.0000000000002429CrossRef

79.

Lin JL, Guillerman RP, Russell H v., et al (2013) Does routine imaging of patients for progression or relapse improve survival in rhabdomyosarcoma?Tumor. Pediatr Blood Cancer 63:202–205. https://doi.org/10.1002/pbc

80.

FaR-RMS: an over-arching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma. ClinicalTrials.gov identifier: https://www.clinicaltrials.gov/ct2/show/NCT04625907. Accessed 02 Feb 20223

81.

World Health Orginazation (2005) Handbook for good clinical research practice (GCP): guidance for implementation. World Health Organization

82.

Proton Technologies AG. Complete guide ti GDPR compliance. In: https://gdpr.eu/. Accessed 26 Jan 2023

83.

Kelly SM, Effeney R, Gaze MN et al (2022) QUARTET: a SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer. Eur J Cancer 172:209–220. https://doi.org/10.1016/j.ejca.2022.05.037CrossRefPubMed

84.

QUARTET Project. In: https://siope.eu/activities/joint-projects/quartet/

85.

Ferrari A, Orbach D, Sparber-Sauer M et al (2022) The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. Eur J Cancer 169:10–19. https://doi.org/10.1016/j.ejca.2022.03.028CrossRefPubMed

86.

Ferrari A, Spunt SL, Sparber-Sauer M et al (2022) Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas. Lancet Child Adolesc Health 6:221–223. https://doi.org/10.1016/S2352-4642(22)00036-0CrossRefPubMed

87.

Wilkinson MD, Dumontier M, IjJ A et al (2016) Comment: the FAIR Guiding Principles for scientific data management and stewardship. Sci Data 3:1–9. https://doi.org/10.1038/sdata.2016.18CrossRef

88.

Davendralingam N, Sebire NJ, Arthurs OJ, Shelmerdine SC (2021) Artificial intelligence in paediatric radiology: future opportunities. British Journal of Radiology 94. https://doi.org/10.1259/bjr.20200975

Title: Imaging in rhabdomyosarcoma: a patient journey
Authors: Isabelle S. A. de Vries
Roelof van Ewijk
Laura M. E. Adriaansen
Anneloes E. Bohte
Arthur J. A. T. Braat
Raquel Dávila Fajardo
Laura S. Hiemcke-Jiwa
Marinka L. F. Hol
Simone A. J. ter Horst
Bart de Keizer
Rutger R. G. Knops
Michael T. Meister
Reineke A. Schoot
Ludi E. Smeele
Sheila Terwisscha van Scheltinga
Bas Vaarwerk
Johannes H. M. Merks
Rick R. van Rijn
Publication date: 27-02-2023
Publisher: Springer Berlin Heidelberg
Keywords: Rhabdomyosarcoma
Soft Tissue Sarcoma
Cytostatic Therapy
Published in: Pediatric Radiology / Issue 4/2023
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI: https://doi.org/10.1007/s00247-023-05596-8

At a glance: The STEP trials

Springer Medicine

Imaging in rhabdomyosarcoma: a patient journey

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

Exploration of the fetal skeleton by ultra-low-dose computed tomography: guidelines from the Fetal Imaging Task Force of the European Society of Paediatric Radiology

Radiologic diagnosis of non-traumatic paediatric head and neck emergencies

European Society of Paediatric Radiology Artificial Intelligence taskforce: a new taskforce for the digital age

Imaging urolithiasis: complications and interventions in children

Introduction to the European Society of Paediatric Radiology 2022 congress special issue

Controversial aspects of imaging in child abuse: a second roundtable discussion from the ESPR child abuse taskforce